MN-VÄRDE-PARTNERS
12.10.2020 13:02:13 CEST | Business Wire | Press release
Värde Partners, a leading global alternative investment firm, today announced the promotion of Jon Fox to the role of President and Andy Lenk to the role of Deputy CEO, effective immediately. These appointments are the latest in a series of transition steps which previously included the appointment of Ilfryn Carstairs as Co-CEO and CIO and the promotions of Brad Bauer and Giuseppe Naglieri as Deputy CIOs.
“I’ve often said that transition is a process involving the entire firm and a number of leaders,” said George Hicks, Co-Founder and Co-CEO. “The appointments reflect the many contributions of Jon and Andy to the success and growth of the firm as well as the leadership experience and capabilities that they will bring to the years ahead.” Previously announced in July 2019, George intends to move to an Executive Chair role at the end of 2021.
Ilfryn Carstairs added, “These promotions are an important step in ensuring that we have the right senior leadership team for the next chapter at Värde. I’ve worked very closely with Jon and Andy for many years and I’m excited to see this elevation in their roles.”
In addition to the President and Deputy CEO roles, Värde announced promotions and role changes within the areas of Financial Services, Insurance, and Capital Markets:
- Elena Lieskovska, Partner, will head a new, dedicated Insurance business after leading this effort within the Financial Services team and previously leading specialty finance investing in Europe.
- Aneek Mamik, Senior Managing Director, will be promoted to Global Co-Head of Financial Services from his current role leading those investments in North America and Asia. He will oversee the global team with Partner Rick Noel.
- Craig Rydqvist, Senior Managing Director and Global Head of Capital Markets based in London, will join the Financial Services team to lead investments outside of North America.
- Missy Dolski, Managing Director, will be promoted to Global Head of Capital Markets from her current role as Head of Capital Markets for North America.
Commenting on these appointments, Deputy CIO Brad Bauer said, “We’re excited to announce these promotions which align proven leadership talent with significant areas of opportunity for our investors. These individuals represent the breadth and depth of talent we have in our investing teams and these promotions are well deserved in light of their contributions.”
Jon Fox is a Partner and the head of the New York office who joined the firm in 2013 in London. He has led the firm’s global Business Development and Investor Relations team, fund and product development, and also oversees Communications and Public Affairs. He is a member of the firm’s Investment Committee and Senior Leadership Committee and plays an important role in general management decisions. In 2018, Jon relocated from London to become the head of the firm’s New York office. He will maintain all existing leadership responsibilities as President and further develop Värde’s global industry relationships.
Jon holds a B.A. from the University of Colorado, an M.B.A. from Columbia Business School and serves on the boards of trustees of the Fire Department of New York (FDNY) Foundation and Oliver Scholars and on the Business Council of the Asia Society.
Andy Lenk joined the firm in 2001 and is a Partner in Minneapolis. As Global Head of Strategy and Portfolio Operations, he works closely with the Co-CEOs on all aspects of firm strategy, finance, talent and operations. He is a member of the firm’s Investment Committee, Senior Leadership Committee and the Enterprise Risk Management Committee. Andy has held many leadership roles for the firm including oversight and development of global Portfolio Operations, Capital Markets, Asset Management and the firm’s Finance and Operations functions. Earlier in his career at Värde, Andy worked in investing teams in both the U.S. and Europe.
Andy received a B.B.A. in Accounting from the University of Wisconsin-Madison and an M.B.A. from the University of Michigan. He is a CPA (inactive).
About Värde Partners
Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $75 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals worldwide with offices in Minneapolis, New York, London, Singapore and other cities in Asia and Europe. For more information, please visit www.varde.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201012005330/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom